Role of the mitochondrial permeability transition in salicylate toxicity to cultured rat hepatocytes: Implications for the pathogenesis of Reye's syndrome

Toxicology and Applied Pharmacology

Volumn 147, Issue 2, 1997, Pages 431-441

  Trost, Lawrence C ^a   Lemasters, John J ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

4 methylyaline cyclosporin; Acetylsalicylic acid; Aspirin; Cyclosporin A; Disorders of fatty acid oxidation; Hepatotoxicity; Hypoglycin; Jamaican Vomiting Sickness; Margosa oil; Mitochondrial permeability transition; Neem oil; Reye's syndrome; Salicylate; Urea cycle disorders; Valproic acid

Indexed keywords

CHLORPROMAZINE; DILTIAZEM; NIFEDIPINE; NISOLDIPINE; SALICYLIC ACID; VERAPAMIL;

ANIMAL CELL; ARTICLE; DRUG CYTOTOXICITY; DRUG EFFECT; FATTY ACID OXIDATION; LIVER CELL; LIVER TOXICITY; MALE; MEMBRANE PERMEABILITY; MITOCHONDRIAL MEMBRANE; NONHUMAN; OXIDATIVE PHOSPHORYLATION; RAT; REYE SYNDROME; TOXICITY TESTING; UREA CYCLE;

EID: 0031413254     PISSN: 0041008X     EISSN: None     Source Type: Journal    
DOI: 10.1006/taap.1997.8313     Document Type: Article

References (69)

1. Bacq Y., Riely C. A. Acute fatty liver of pregnancy: The hepatologist's view. Gastroenterologist. 1:1993;257-264.
2. Beales D., McLean A. E. M. Protection in the late stages of paracetamol-induced liver cell injury with fructose, cyclosporin A, and trifluoperazine. Toxicology. 107:1996;201-208.
3. Bernardi P., Broekemeier K. M., Pfeiffer D. R. Recent progress on regulation of the mitochondrial permeability transition pore; a cyclosporin sensitive pore in the inner-mitochondrial membrane. J. Bioenerg. Biomembr. 26:1994;509-517.
4. Bernardi P., Vassanelli S., Veronese P., Colonna R., Szabo I., Zoratti M. Modulation of the mitochondrial permeability transition pore: Effect of protons and divalent cations. J. Biol. Chem. 267:1992;2934-2939.
5. 2+. Biochem. Pharmacol. 50:1995;497-500.
6. 2+. FEBS Lett. 304:1992;192-194.
7. Broekemeier K. M., Dempsey M. E., Pfeiffer D. R. Cyclosporin A is a potent inhibitor of the inner membrane permeability transition in liver mitochondria. J. Biol. Chem. 264:1989;7826-7830.
8. Broekemeier K. M., Pfeiffer D. R. Inhibition of the mitochondrial permeability transition by cyclosporin A during long timeframe experiments: A relationship between pore opening and the activity of mitochondrial phospholipases. Biochemistry. 34:1995;16440-16445.
9. Brown R. E., Forman D. T. The biochemistry of Reye's syndrome. CRC Crit. Rev. Clin. Lab. Sci. 17:1982;247-297.
10. Casteels-Van Daele M. Reye's syndrome or side-effects of anti-emetics? Eur. J. Pediatr. 150:1991;456-459.
11. MMWR. 29:1980;532-539.
12. 2+. Biophys. J. 66:1994;942-952.
13. 2+. J. Clin. Invest. 87:1991;778-786.
14. Costantini P., Petronilli V., Colonna R., Bernardi P. On the effects of paraquat on isolated mitochondria. Evidence that paraquat causes opening of the cyclosporin A-sensitive permeability transition pore synergistically with nitric oxide. Toxicology. 99:1995;77-88.
15. +2. Biochem. J. 255:1988;357-360.
16. Danan G., Trunet P., Bernuau J., Degott C., Babany G., Pessayre D., Rueff B., Benhamou J. P. Pirprofen-induced fulminant hepatitis. Gastroenterol. 89:1985;210-213.
17. Duchen M. P., McGuinness O., Brown L. A., Crompton M. On the involvement of cyclosporin A sensitive mitochondrial pore in myocardial reperfusion injury. Cardiovasc. Res. 27:1993;1790-1794.
18. Flower R. J., Moncada S., Vane J. R. Analgesic-antipyretics and anti-inflammatory agents; drugs employed in the treatment of gout. The Pharmacological Basis of Therapeutics. 1985;Macmillan, New York. p. 674-715.
19. Fournier N., Ducet G., Crevat A. Action of cyclosporine on mitochondrial calcium fluxes. J. Bioenerg. Biomembr. 19:1987;297-303.
20. 2+. Biochim. Biophys. Acta. 117:1993;1-7.
21. Gerber N., Dickinson R. G., Harland R. C., Lynn R. K., Houghton D., Antonias J. I., Schimschock J. C. Reye-like syndrome associated with valproic acid therapy. J. Pediatr. 95:1979;142-144.
22. Glasgow J. F. T., Moore R. Current concepts in Reye's syndrome. Brit. J. Hosp. Med. 50:1993;599-604.
23. Gores G. J., Nieminen A.-L., Fleishman K. E., Dawson T. L., Herman B., Lemasters J. J. Extracellular acidosis delays onset of cell death in ATP-depleted hepatocytes. Am. J. Physiol. 255:1988;C315-C322.
24. Griffiths E. J., Halestrap A. P. Protection by cyclosporin A of ischemia/reperfusion-induced damage in isolated rat hearts. J. Mol. Cell. Cardiol. 25:1993;1461-1469.
25. Gunter T. E., Pfeiffer D. R. Mechanisms by which mitochondria transport calcium. Am. J. Physiol. 258:1990;C755-C786.
26. Heubi J. E., Partin J. C., Partin J. S., Schubert W. K. Reye's syndrome: Current concepts. Hepatology. 7:1987;155-164.
27. Imberti R., Nieminen A.-L., Herman B., Lemasters J. J. Synergism of cyclosporin A and phospholipase inhibitors in protection against lethal injury to rat hepatocytes from oxidant chemicals. Res. Commun. Chem. Pathol. Pharmacol. 78:1992;27-38.
28. Imberti R., Nieminen A.-L., Herman B., Lemasters J. J. Mitochondrial and glycolytic dysfunction in lethal injury to hepatocytes byt. J. Pharmacol. Exp. Ther. 265:1993;392-400.
29. 2+. Toxicology. 95:1995;155-166.
30. Koga Y., Yoshida I., Kimura A., Yoshino M., Yamashita F., Sinniah D. Inhibition of mitochondrial function by Margosa oil: Possible implications in the pathogenesis of Reye's syndrome. Pediatr. Res. 22:1987;184-187.
31. Kroemer G., Zamzami N., Susin S. A. Mitochondrial control of apoptosis. Immunol. Today. 18:1997;44-51.
32. Landon E. J., Naukam R. J., Sastry B. V. R. Effects of calcium channel blocking agents on calcium and centrilobular necrosis in the liver of rats treated with hepatotoxic agents. Biochem. Pharmacol. 35:1986;697-705.
33. 2+. Arch. Biochem. Biophys. 244:1986;773-786.
34. Martens M. E., Lee C.-P. Reye's syndrome: salicylates and mitochondrial functions. Biochem. Pharmacol. 33:1984;2869-2876.
35. Mauger J. P., Claret M. Calcium channels in hepatocytes. J. Hepatol. 7:1988;278-282.
36. Michael A. D., Whiting R. L. Cellular action of nicardipine. Am. J. Cardiol. 64:1989;3H-7H.
37. Mitchell P. Keilin's respiratory chain concept and its chemiosmotic consequences. Science. 206:1979;1148-1159.
38. Nieminen A.-L., Gores G. J., Bond J. M., Imberti R., Herman B., Lemasters J. J. A novel cytotoxicity assay using a multiwell fluorescence scanner. Toxicol. Appl. Pharmacol. 115:1992;147-155.
39. Nieminen A.-L., Saylor A. K., Tesfai S. A., Herman B., Lemasters J. J. Contribution of the mitochondrial permeability transition to lethal injury after exposure of hepatocytes tot. Biochem. J. 307:1995;99-106.
40. Novgorodov S. A., Gudz T. I., Brierley G. P., Pfeiffer D. R. Magnesium ion modulates the sensitivity of the mitochondrial permeability transition pore to cyclosporin A and ADP. Arch. Biochem. Biophys. 311:1994;219-228.
41. Partin J. C., Shubert W. K., Partin J. S. Mitochondrial ultrastructure in Reye's syndrome (encephalopathy and fatty degeneration of the viscera). New Engl. J. Med. 285:1971;1339-1343.
42. 2+. Am. J. Physiol. 268:1995;C676-685.
43. Petronilli V., Costantini P., Scorrano L., Colonna R., Passamonti S., Bernardi P. The voltage sensor of the mitochondrial permeability transition pore is tuned by the oxidation-reduction state of vicinal thiols. J. Biol. Chem. 269:1994;16638-16642.
44. Pinsky P. F., Hurwitz P. F., Schonberger L. B., Gunn W. J. Reye's syndrome and aspirin. Evidence for a dose-response effect. J. Am. Med. Assoc. 260:1988;657-661.
45. +. Am. J. Physiol. 273:1997;C1783-C1792.
46. 2+. FASEB J. 7:1993;453-463.
47. Reye R. D. K., Morgan G., Baral J. Encephalopathy and fatty degeneration of the viscera: A disease entity in childhood. Lancet. ii:1963;749-752.
48. Rodgers G. C. Jr., Weiner L. B., McMillan J. A. Salicylate and Reye syndrome. Lancet. i:1982;616.
49. Saxena K., Henry T. R., Solem L. E., Wallace K. B. Enhanced induction of the mitochondrial permeability transition following acute menadione administration. Arch. Biochem. Biophys. 317:1995;79-84.
50. Segalman T. Y., Lee C. P. Reye's syndrome: Plasma-induced alterations in mitochondrial structure and function. Arch. Biochem. Biophys. 214:1982;522-530.
51. Sherratt H. S. A. Hypoglycin, the famous toxin of the unripe Jamaican Ackee fruit. Trends Pharmacol. Sci. 1986;186-191.
52. Schreier M. H., Baumann G., Zenke G. Inhibition of T-cell signaling pathways by immunophilin drug complexes: are side effects inherent to immunosuppressive properties? Tranplant. Proc. 25:1993;502-507.
53. Sinniah D., Baskaran G. Margosa oil poisoning as a cause of Reye's syndrome. Lancet. i:1981;487-489.
54. Sippel H., Stauffert I., Estler C.-J. Protective effect of various calcium antagonists against an experimentally induced calcium overload in isolated hepatocytes. Biochem. Pharmacol. 46:1993;1937-1944.
55. Starko K. M., Ray C. G., Dominguez L. B., Stromberg W. L., Woodall D. F. Reye's syndrome and salicylate use. Pediatrics. 66:1980;859-864.
56. Starko K. M., Mullick F. G. Hepatic and cerebral pathology findings in children with fatal salicylate intoxication: Further evidence for a causal relation between salicylate and Reye's syndrome. Lancet. i:1983;326-329.
57. M.M.W.R. 31:1982;289-290.
58. Szabo I., Zoratti M. The giant channel of the inner mitochondrial membrane is inhibited by cyclosporin A. J. Biol. Chem. 266:1991;3376-3379.
59. Thurman R. G., Apel E., Badr M., Lemasters J. J. Protection of liver by calcium entry blockers. Ann. N. Y. Acad. Sci. 522:1988;757-770.
60. Tomasova H., Nevoral J., Pachi J., Kincl V. Aspirin esterase activity and Reye's syndrome. Lancet. ii:1984;43.
61. 2+. Liver. 14:1994;103-108.
62. Tonsgard J. H., Getz G. S. Effect of Reye's syndrome serum on isolated chinchilla liver mitochondria. J. Clin. Invest. 76:1985;816-825.
63. Trost L. C., Lemasters J. J. The mitochondrial permeability transition: A new pathophysiological mechanism for Reye's syndrome and toxic liver injury. J. Pharmacol. Exp. Ther. 278:1996;1000-1005.
64. Ulrich R. G., Bacon J. A., Branstetter D. G., Cramer C. T., Funk G. M., Hunt C. E., Petrella D. K., Sun E. L. Induction of a hepatic toxic syndrome in the dutch-belted rabbit by a quinoxalinone anxiolytic. Toxicology. 98:1994;187-198.
65. Venerando R., Miotto G., Pizzo P., Rizzuto R., Siliprandi N. Mitochondrial alterations induced by aspirin in rat hepatocytes expressing mitochondrial targeted green fluorescent protein (mtGFP). FEBS Lett. 382:1996;256-260.
66. Waldman R. J., Hall W. N., McGee H., VanAmburg G. Aspirin as a risk factor in Reye's syndrome. J. Am. Med. Assoc. 247:1982;3089-3094.
67. You K.-S. Salicylate and mitochondrial injury in Reye's syndrome. Science. 221:1983;163-165.
68. Zahrebelski G., Nieminen A.-L., Al-Ghoul K., Qian T., Herman B., Lemasters J. J. Progression of subcellular changes during chemical hypoxia to cultured rat hepatocytes: a laser scanning confocal microscopic study. Hepatology. 21:1995;1361-1372.
69. Zoratti M., Szabo I. The mitochondrial permeability transition. Biochim. Biophys. Acta. 1241:1995;139-176.